What did @hacksmithsbackup actually say?
The creator ran through five peptides, thymalin, thymosin alpha-1, VIP, LL-37, and KPV, each pitched as a potential tool for people with autoimmune conditions. The framing was measured in places: phrases like "might be able to help" and "worth looking into" show some restraint. But describing VIP as "a game changer for people with auto immune gut issues like Crohn's disease" is a stronger claim than the evidence currently supports. The list itself is not random, these are peptides that have actually appeared in immunology research. The problem is the gap between "appeared in research" and "works in humans with autoimmune disease" is enormous, and the video largely glosses over it.
Does the science back this up?
Partially, and it depends heavily on which peptide you're asking about. Thymosin alpha-1 has the strongest human evidence base of the five. It is an FDA-approved drug in some countries (Zadaxin) and has been studied in sepsis, hepatitis B, and immune reconstitution. A 2020 multicenter trial (Liu et al., 2020, Journal of Infection) found thymosin alpha-1 improved immune function markers in severe COVID-19 patients. That is real data. Thymalin has decades of Eastern European research behind it, mostly Soviet-era studies that are difficult to independently verify and were never run to modern clinical trial standards. VIP has shown anti-inflammatory effects in animal models of colitis and rheumatoid arthritis (Gonzalez-Rey et al., 2006, Journal of Clinical Investigation), but human trial data for autoimmune indications is thin. LL-37 and KPV are primarily at the preclinical stage for immune modulation, with KPV showing gut anti-inflammatory effects in murine colitis models (Dalmasso et al., 2008, Gastroenterology) but no robust human trials yet.
What did they get wrong (or right)?
Credit where it is due: the creator did not claim any of these peptides cure autoimmune disease. The conditional language throughout is better than a lot of peptide content on TikTok. Thymosin alpha-1's role in immune surveillance is also genuinely supported, so that framing is reasonable.
Where the video stumbles is in treating all five peptides as roughly equivalent in their evidence base. They are not. Calling VIP "a game changer" for Crohn's disease is not supported by human clinical evidence. The existing VIP research in inflammatory bowel disease is almost entirely animal model data. Similarly, the claim that LL-37 is "really useful" for Lyme disease or mold illness leans on theoretical immune-modulating properties, not clinical outcomes research in those specific conditions. Linking LL-37 to mold illness in particular edges into territory that lacks any meaningful clinical grounding. KPV for psoriasis and autoimmune skin conditions is biologically plausible but unproven in humans.
- Thymalin: plausible, limited modern evidence
- Thymosin alpha-1: strongest human data of the group
- VIP: promising preclinical data, weak human trial evidence for autoimmune use
- LL-37: early-stage, claims about Lyme and mold illness are not well-supported
- KPV: interesting mechanism, preclinical only for most indications mentioned
What should you actually know?
Autoimmune disease is not a single condition with a single mechanism, and that matters here. Crohn's disease, psoriasis, and Lyme-associated illness involve different immune pathways, different tissues, and different treatment targets. A peptide that modulates one arm of immune function is not automatically useful across all of them. The video presents these five as a coherent toolkit, but immune modulation cuts both ways. Suppressing an overactive immune response in one context could theoretically impair pathogen clearance in another. That is not a hypothetical concern for patients who are already immunocompromised.
None of these peptides are FDA-approved for autoimmune indications in the United States. Several are available through compounding pharmacies, but compounded peptides are not equivalent to pharmaceutical-grade products and carry their own regulatory and quality considerations. If you have an autoimmune condition and are curious about peptide therapy, that conversation belongs with a physician who can review your specific diagnosis, your current medications, and your immune profile, not a five-minute TikTok.